flynn	10.1007/s00280-014-2668-5	<http://dx.doi.org/10.1007/s00280-014-2668-5>; rel="canonical", <http://link.springer.com/content/pdf/10.1007/s00280-014-2668-5>; version="vor"; rel="item"	<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:j.0="http://purl.org/dc/terms/" xmlns:j.1="http://prismstandard.org/namespaces/basic/2.1/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:j.2="http://purl.org/ontology/bibo/" xmlns:j.3="http://xmlns.com/foaf/0.1/"><rdf:Description rdf:about="http://dx.doi.org/10.1007/s00280-014-2668-5"><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/briant-f-fruth-whudndphdgdx"><j.3:name>Briant F. Fruth</j.3:name><j.3:familyName>Fruth</j.3:familyName><j.3:givenName>Briant F.</j.3:givenName></j.3:Person></j.0:creator><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/henry-pitot-whudndphdgdx"><j.3:name>Henry Pitot</j.3:name><j.3:familyName>Pitot</j.3:familyName><j.3:givenName>Henry</j.3:givenName></j.3:Person></j.0:creator><j.1:endingPage>493</j.1:endingPage><j.0:title>Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study</j.0:title><j.1:startingPage>485</j.1:startingPage><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/jaime-r-merchan-whudndphdgdx"><j.3:name>Jaime R. Merchan</j.3:name><j.3:familyName>Merchan</j.3:familyName><j.3:givenName>Jaime R.</j.3:givenName></j.3:Person></j.0:creator><j.0:isPartOf><j.2:Journal rdf:about="http://id.crossref.org/issn/0344-5704"><j.1:issn>1432-0843</j.1:issn><j.2:issn>1432-0843</j.2:issn><owl:sameAs>urn:issn:1432-0843</owl:sameAs><owl:sameAs>urn:issn:0344-5704</owl:sameAs><j.0:title>Cancer Chemotherapy and Pharmacology</j.0:title><j.1:issn>0344-5704</j.1:issn><j.2:issn>0344-5704</j.2:issn></j.2:Journal></j.0:isPartOf><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/tom-fitch-whudndphdgdx"><j.3:name>Tom Fitch</j.3:name><j.3:familyName>Fitch</j.3:familyName><j.3:givenName>Tom</j.3:givenName></j.3:Person></j.0:creator><owl:sameAs rdf:resource="doi:10.1007/s00280-014-2668-5"/><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/william-j-maples-whudndphdgdx"><j.3:name>William J. Maples</j.3:name><j.3:familyName>Maples</j.3:familyName><j.3:givenName>William J.</j.3:givenName></j.3:Person></j.0:creator><j.1:volume>75</j.1:volume><j.2:pageStart>485</j.2:pageStart><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/patrick-j-flynn-whudndphdgdx"><j.3:name>Patrick J. Flynn</j.3:name><j.3:familyName>Flynn</j.3:familyName><j.3:givenName>Patrick J.</j.3:givenName></j.3:Person></j.0:creator><j.2:doi>10.1007/s00280-014-2668-5</j.2:doi><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/charles-erlichman-whudndphdgdx"><j.3:name>Charles Erlichman</j.3:name><j.3:familyName>Erlichman</j.3:familyName><j.3:givenName>Charles</j.3:givenName></j.3:Person></j.0:creator><j.1:doi>10.1007/s00280-014-2668-5</j.1:doi><j.0:publisher>Springer Nature</j.0:publisher><j.0:date rdf:datatype="http://www.w3.org/2001/XMLSchema#date" >2015-01-03</j.0:date><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/rui-qin-whudndphdgdx"><j.3:name>Rui Qin</j.3:name><j.3:familyName>Qin</j.3:familyName><j.3:givenName>Rui</j.3:givenName></j.3:Person></j.0:creator><j.2:pageEnd>493</j.2:pageEnd><j.2:volume>75</j.2:volume><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/glenn-liu-whudndphdgdx"><j.3:name>Glenn Liu</j.3:name><j.3:familyName>Liu</j.3:familyName><j.3:givenName>Glenn</j.3:givenName></j.3:Person></j.0:creator><j.0:identifier>10.1007/s00280-014-2668-5</j.0:identifier><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/joel-picus-whudndphdgdx"><j.3:name>Joel Picus</j.3:name><j.3:familyName>Picus</j.3:familyName><j.3:givenName>Joel</j.3:givenName></j.3:Person></j.0:creator><owl:sameAs rdf:resource="info:doi/10.1007/s00280-014-2668-5"/></rdf:Description></rdf:RDF>
